Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

被引:41
|
作者
Yao, Zhangyu [1 ]
Wei, Xueying [1 ]
Wu, Xiaoming [1 ]
Katz, Jonathan L. [2 ]
Kopajtic, Theresa [2 ]
Greig, Nigel H. [3 ]
Sun, Hongbin [1 ]
机构
[1] China Pharmaceut Univ, Coll Pharm, Ctr Drug Discovery, Nanjing 210009, Peoples R China
[2] Natl Inst Drug Abuse, Psychobiol Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[3] NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA
关键词
Tetrabenazine enantiomers; Dihydrotetrabenazine stereoisomers; Resolution; Huntington's chorea; VMAT2; Hyperkinetic disorders; MONOAMINE TRANSPORTER; MOVEMENT-DISORDERS; METABOLITE; EPOXIDES; EMETINE; BINDING; DRUGS;
D O I
10.1016/j.ejmech.2011.02.046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tetrabenazine (TBZ) ((+/-)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (+/-)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (K-i = 4.47 nM) was 8000-fold more potent than ()-1 (K-i = 36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: K-i= 3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1841 / 1848
页数:8
相关论文
共 50 条
  • [1] Structural mechanisms for VMAT2 inhibition by tetrabenazine
    Dalton, Michael P.
    Cheng, Mary H.
    Bahar, Ivet
    Coleman, Jonathan
    BIOPHYSICAL JOURNAL, 2024, 123 (03) : 116A - 116A
  • [2] Structural mechanisms for VMAT2 inhibition by tetrabenazine
    Dalton, Michael P.
    Cheng, Mary Hongying
    Bahar, Ivet
    Coleman, Jonathan A.
    ELIFE, 2024, 12
  • [3] VMAT2 Inhibitors in Neuropsychiatric Disorders
    Tarakad, Arjun
    Jimenez-Shahed, Joohi
    CNS DRUGS, 2018, 32 (12) : 1131 - 1144
  • [4] Synthesis and biological evaluation of tetrabenazine derivatives for brain vesicular monoamine transporter VMAT2 imaging
    Papin, Caroline
    Alagille, David
    Lee, Sharon
    Barret, Olivier
    Baldwin, Ronald M.
    Tamagnan, Gilles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [5] VMAT2 Inhibitors in Neuropsychiatric Disorders
    Arjun Tarakad
    Joohi Jimenez-Shahed
    CNS Drugs, 2018, 32 : 1131 - 1144
  • [6] VMAT2 inhibitors for the treatment of tardive dyskinesia
    Scorr, Laura M.
    Factor, Stewart A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 : 43 - 47
  • [7] VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
    Warren, Barbara
    Vanderhoef, Dawn
    Johnson, Jessica
    ISSUES IN MENTAL HEALTH NURSING, 2022, 43 (01) : 22 - 31
  • [8] Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands
    Zheng, Pinguan
    Lieberman, Brian P.
    Choi, Seok Rye
    Ploeessl, Karl
    Kung, Hank F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (11) : 3435 - 3438
  • [9] Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas
    Tsao, Hsin-Hsin
    Skovronsky, Daniel M.
    Lin, Kun-Ju
    Yen, Tzu-Chen
    Wey, Shiaw-Pyng
    Kung, Mei-Ping
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (07) : 1029 - 1034
  • [10] New generation VMAT2 inhibitors induced parkinsonism
    Vasireddy, Rani Priyanka
    Sokola, Brent
    Guduru, Zain
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2020, 3